DK171421B1 - Polysaccharidforbindelse og fremgangsmåde til fremstilling deraf - Google Patents

Polysaccharidforbindelse og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK171421B1
DK171421B1 DK593285A DK593285A DK171421B1 DK 171421 B1 DK171421 B1 DK 171421B1 DK 593285 A DK593285 A DK 593285A DK 593285 A DK593285 A DK 593285A DK 171421 B1 DK171421 B1 DK 171421B1
Authority
DK
Denmark
Prior art keywords
polysaccharide
protein
conjugate
conjugates
liters
Prior art date
Application number
DK593285A
Other languages
Danish (da)
English (en)
Other versions
DK593285A (da
DK593285D0 (da
Inventor
Stephen Marburg
Richard L Tolman
Deborah A Jorn
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DK593285D0 publication Critical patent/DK593285D0/da
Publication of DK593285A publication Critical patent/DK593285A/da
Application granted granted Critical
Publication of DK171421B1 publication Critical patent/DK171421B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK593285A 1984-12-20 1985-12-19 Polysaccharidforbindelse og fremgangsmåde til fremstilling deraf DK171421B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68440184A 1984-12-20 1984-12-20
US68440184 1984-12-20

Publications (3)

Publication Number Publication Date
DK593285D0 DK593285D0 (da) 1985-12-19
DK593285A DK593285A (da) 1986-06-21
DK171421B1 true DK171421B1 (da) 1996-10-21

Family

ID=24747887

Family Applications (2)

Application Number Title Priority Date Filing Date
DK593285A DK171421B1 (da) 1984-12-20 1985-12-19 Polysaccharidforbindelse og fremgangsmåde til fremstilling deraf
DK98695A DK171951B1 (da) 1984-12-20 1995-09-07 Fremgangsmaade til solubilisering af ikke-polyanioniske polysaccharider og fremgangsmaade til modificering af de solubiliserede neutrale polysaccharider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98695A DK171951B1 (da) 1984-12-20 1995-09-07 Fremgangsmaade til solubilisering af ikke-polyanioniske polysaccharider og fremgangsmaade til modificering af de solubiliserede neutrale polysaccharider

Country Status (20)

Country Link
US (1) US4830852A (el)
EP (1) EP0186576B1 (el)
JP (1) JPH0825900B2 (el)
KR (1) KR910002704B1 (el)
CN (1) CN1017867B (el)
AT (1) ATE78492T1 (el)
AU (1) AU584149B2 (el)
CA (1) CA1256250A (el)
CY (1) CY1766A (el)
DE (1) DE3586398T2 (el)
DK (2) DK171421B1 (el)
ES (1) ES8701498A1 (el)
GR (1) GR853071B (el)
HK (1) HK18794A (el)
IE (1) IE58977B1 (el)
IL (1) IL77293A (el)
NZ (1) NZ214503A (el)
PT (1) PT81656B (el)
SG (1) SG14294G (el)
ZA (1) ZA859676B (el)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
EP0270295A3 (en) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Conjugate vaccine
US5116612A (en) * 1987-06-23 1992-05-26 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
EP0300102B1 (en) * 1987-07-21 1993-03-24 The Stolle Research And Development Corporation Improved method of obtaining immune regulatory factors by mammal immunization
ATE106249T1 (de) * 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
EP0399001B1 (en) * 1988-02-01 1994-07-27 Praxis Biologics, Inc. T-cell epitope as carriers molecule for conjugate vaccines
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
EP0606921B1 (en) * 1989-03-09 2000-08-02 American Cyanamid Company Method of isolating haemophilus influenzae protein E
US4963534A (en) * 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US5466681A (en) * 1990-02-23 1995-11-14 Microcarb, Inc. Receptor conjugates for targeting penicillin antibiotics to bacteria
US5241072A (en) * 1990-05-25 1993-08-31 Genzyne Corporation Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof
CA2047031A1 (en) * 1990-07-19 1992-01-20 Stephen Marburg Peptide-polysaccharide-protein conjugate vaccines
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
IL99077A0 (en) * 1990-08-13 1992-07-15 Merck & Co Inc New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US7279162B1 (en) * 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5843463A (en) * 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
AU685047B2 (en) * 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
DE122009000058I1 (de) * 1993-09-22 2009-12-31 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
US5866135A (en) 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
AU722315B2 (en) 1997-01-21 2000-07-27 Pasteur Merieux Serums Et Vaccins Polysaccharide-peptide conjugates
DE69826851T2 (de) * 1997-04-24 2005-02-10 Henry M. Jackson Foundation For The Advancement Of Military Medicine Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
EP1113817B1 (en) * 1998-09-18 2005-04-20 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
US10919956B2 (en) 2002-11-12 2021-02-16 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7723087B2 (en) * 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
JP5080243B2 (ja) 2004-04-21 2012-11-21 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ポリ−Ｎ−アセチルグルコサミン（ＰＮＡＧ／ｄＰＮＡＧ）結合ペプチドおよびその使用方法
JP4841546B2 (ja) * 2005-03-31 2011-12-21 生化学工業株式会社 新規抗ヘパラン硫酸抗体、ヘパラン硫酸の検出方法、及びヘパラン硫酸検出キット
JP2009500457A (ja) * 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド 毒性の低下した免疫抑制モノクローナル抗体を使用する自己免疫疾患の治療法
EP2037961B1 (en) 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2008079713A2 (en) * 2006-12-21 2008-07-03 Macrogenics Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
RU2532911C2 (ru) * 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
CA2766418C (en) * 2009-06-22 2016-03-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN109563695B (zh) 2016-07-29 2021-09-03 住友建机株式会社 挖土机、挖土机用控制阀门
SI3544637T1 (sl) 2016-11-25 2021-02-26 Glaxosmithkline Biologicals S.A. Nativni OMV-antigen konjugati in njihova uporaba
BR112019010227A2 (pt) 2016-11-25 2019-10-08 Glaxosmithkline Biologicals Sa conjugado imunogênico, processo para preparação de conjugado imunogênico, composição imunogênica, vacina, e, uso de nomv
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102028693B1 (ko) * 2017-04-27 2019-10-04 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
CN107261130A (zh) * 2017-06-29 2017-10-20 云南沃森生物技术股份有限公司 一种用dsc作为活化剂的细菌多糖蛋白结合疫苗的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1115210A (en) * 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8200751L (sv) * 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
JPS58167519A (ja) * 1982-03-30 1983-10-03 Teijin Ltd 細胞毒性複合体及びその製造法
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency

Also Published As

Publication number Publication date
NZ214503A (en) 1990-02-26
ZA859676B (en) 1986-08-27
HK18794A (en) 1994-03-11
DE3586398D1 (de) 1992-08-27
ES8701498A1 (es) 1986-12-01
PT81656B (pt) 1988-04-21
DK171951B1 (da) 1997-08-25
IE58977B1 (en) 1993-12-15
EP0186576B1 (en) 1992-07-22
ATE78492T1 (de) 1992-08-15
KR910002704B1 (ko) 1991-05-03
ES550152A0 (es) 1986-12-01
US4830852A (en) 1989-05-16
JPH0825900B2 (ja) 1996-03-13
CN1017867B (zh) 1992-08-19
AU584149B2 (en) 1989-05-18
IE853227L (en) 1986-06-20
CA1256250A (en) 1989-06-20
DE3586398T2 (de) 1993-01-07
IL77293A (en) 1990-11-05
AU5146885A (en) 1986-06-26
GR853071B (el) 1986-04-21
CY1766A (en) 1994-07-15
EP0186576A2 (en) 1986-07-02
DK593285A (da) 1986-06-21
KR860004923A (ko) 1986-07-16
EP0186576A3 (en) 1989-01-25
PT81656A (en) 1986-01-01
DK593285D0 (da) 1985-12-19
JPS61186400A (ja) 1986-08-20
DK98695A (da) 1995-09-07
CN85108890A (zh) 1986-11-19
SG14294G (en) 1994-06-10

Similar Documents

Publication Publication Date Title
DK171421B1 (da) Polysaccharidforbindelse og fremgangsmåde til fremstilling deraf
DK171420B1 (da) Kovalent-modificeret bakterielt polysaccharid/protein-konjugat, fremgangsmåde til fremstilling deraf og præparat omfattende et polysaccharid/protein-konjugat
US4882317A (en) Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5371197A (en) Protein-dimeric polysaccharide conjugate vaccine
TW201934140A (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物
TW201945028A (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物
TW201808328A (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
EP0117783A2 (en) Coupled haemophilus inflenzae type B vaccine
JPH05148157A (ja) 肺炎連鎖球菌からの多糖抗原
WO2015144031A1 (zh) 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
JPH0794472B2 (ja) 肺炎連鎖球菌多糖結合体ワクチン
TW201811362A (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
JP2022513562A (ja) 肺炎連鎖球菌の精製された莢膜多糖
JP2017531662A (ja) 改善されたコンジュゲーション方法及びそれから得られる合成オリゴ糖／タンパク質のコンジュゲート
CN110248681A (zh) nOMV-抗原缀合物及其用途
US11420993B2 (en) Semi-synthetic meningococcal conjugate vaccine
KR20190069479A (ko) 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법
CN104096226B (zh) 一种增强4价流行性脑膜炎球菌多糖蛋白结合物免疫原性的方法
CN104096227B (zh) 一种增强4价流行性脑膜炎球菌多糖蛋白结合物免疫原性的方法
CA2047043A1 (en) Class ii protein of the outer membrane of neisseria meningitidis having immune enhancement properties
BG60630B2 (bg) Ковалентно модифицирани полианионни бактериални полизахариди,техни стабилни ковалентни конюгати с имуногенни протеини свързани с хибридни молекули,
CA2047030A1 (en) Class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK